SCHEMBL6153495

SCHEMBL6153495

NC(=O)c1ccc(NC2CCCNCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.45
FLT3 P36888 1/20 0.43
CHEK1 O14757 2/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
PRKD1 Q15139 4/20 0.41
PRKD2 Q9BZL6 4/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
AURKA O14965 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4144350 0.94 IRAK4 (0.45) SYKIRAK4CYP2C9HPGDHDAC3
Hydrochloric Acid SCHEMBL6153321 0.92 IRAK4 (0.44) SYKIRAK4CYP2C9HPGDHDAC3
SCHEMBL6154228 0.88 FLT3 (0.54) SYKFLT3CHEK1AURKARPS6KB1
SCHEMBL12998885 0.86 SYK (0.52) SYKCYP2C9HPGDCCNA2CDK2
SCHEMBL29990331 0.85 RPS6KB1 (0.46) SYKFLT3CHEK1PRKD1PRKD2
SCHEMBL6156878 0.85 RPS6KB1 (0.46) SYKFLT3CHEK1PRKD1PRKD2
SCHEMBL10425208 0.84 SYK (0.51) SYKCYP2C9HPGDEPHX1
SCHEMBL18361381 0.83 NPC1 (0.52) CYP2C9HPGD
SCHEMBL27932778 0.82 SYK (0.48) SYKFLT3CYP2C9HPGD
Hydrochloric Acid SCHEMBL21043570 0.82 NPC1 (0.51) CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 SYK 1613/4885FLT3 2536/4885CHEK1 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.